SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer
Authors:
- H. ChungHCH. Chung
- K. LeeKLK. Lee
- W. KimWKW. Kim
- J. GainorJGJ. Gainor
- N. LakhaniNLN. Lakhani
- L. ChowLCL. Chow
- W. MessersmithWMW. Messersmith
- P. FanningPFP. Fanning
- P. SquiffletPSP. Squifflet
- F. JinFJF. Jin
- A. ForgieAFA. Forgie
- H. WanHWH. Wan
- 1 July 2021
- journal article
- abstracts
- Published by Elsevier in Annals of Oncology
- Vol. 32, S215-S216